Omeros Corporation (NASDAQ: OMER) is a Healthcare company (Biotechnology) with a market capitalization of $991M. The Maz Rating grades it against the other companies in its sector.
Omeros Corporation's current Maz Rating and its five factor grades are for members: log in to see them.
At $13.69, Omeros Corporation trades at 10.5x trailing earnings and 31.4x sales, with an EV/EBITDA of 7.6. Over the last twelve months it generated about $32M of revenue and $94M of net income. It runs a gross margin of 93.6%, an operating margin of -109.1% and a net margin of 256.1%. It shows return on equity of -120.8%, return on invested capital of -21.7% and a free cash flow yield of -3.1%. On the balance sheet: a debt-to-equity ratio of -0.10 and a current ratio of 2.27. Over the past 52 weeks the share price ranged from $6.70 to $21.24, with a beta of 2.57.
Omeros Corporation does not currently pay a dividend.
19 Wall Street analyst ratings cover the stock: 1 Strong Buy, 11 Buy, 5 Hold and 2 Sell, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Omeros Corporation is a biopharmaceutical firm with commercialized products, actively engaged in the discovery, development, and market introduction of both small-molecule and protein-based therapies, including treatments for rare diseases. The company's therapeutic endeavors primarily focus on inflammatory conditions, illnesses mediated by the complement system, cancers linked to immune system dysregulation, and disorders characterized by addiction or compulsion. Its robust clinical pipeline features several promising candidates. Narsoplimab (also known as OMS721 or MASP-2), a leading asset, has successfully concluded pivotal trials for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (HSCT-TMA). This drug is also currently undergoing Phase III clinical evaluation for immunoglobulin A nephropathy (IgAN) and atypical hemolytic uremic syndrome (aHUS), in addition to a Phase II trial investigating its potential for treating COVID-19. Further expanding its clinical portfolio, Omeros is developing PPAR? (OMS405) in Phase II for opioid and nicotine dependence. PDE7 (OMS527) is progressing through Phase I studies for addiction, compulsive disorders, and movement disorders. Additionally, MASP-3 (OMS906) is currently in Phase I trials for paroxysmal nocturnal hemoglobinuria (PNH) and other conditions involving the alternative complement pathway. Beyond its clinical efforts, the company maintains a dynamic preclinical program. This includes small-molecule inhibitors targeting MASP-2, which are being explored for applications in aHUS, IgAN, HSCT-TMA, and age-related macular degeneration. Also in development is a next-generation, longer-acting antibody that targets MASP-2, alongside MASP-3 small-molecule inhibitors designed to address PNH and other alternative pathway disorders. Omeros's preclinical research further encompasses GPR174 inhibitors, as well as Chimeric Antigen Receptor (CAR) T-Cell and Adoptive T-Cell Therapies for various oncological indications. The company is also investigating G protein-coupled receptor targets for a broad spectrum of diseases, including immunological, immuno-oncological, metabolic, central nervous system (CNS), cardiovascular, musculoskeletal, and other conditions. Established in 1994, Omeros Corporation is headquartered in Seattle, Washington.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, Omeros Corporation (OMER) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 14.0% / 30% · (Cash+Inv) / Mkt Cap (36m) 7.23% / 30% · Interest income / Revenue 5.20% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 14.0% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 7.23% / 33% · Receivables / Mkt Cap (36m) 1.75% / 49% · Interest income / Revenue 5.20% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 14.0% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 7.23% / 33.33% · Receivables / Mkt Cap (24m) 1.75% / 33.33% · Interest income / Revenue 5.20% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 68.8% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 46.6% / 33.33% · Receivables / Avg Assets (4Q) 10.3% / 33.33% · Interest income / Revenue 5.20% / 5% | Fail |
| FTSE | Debt / Total Assets 74.5% / 33.33% · (Cash+ST Inv) / Total Assets 38.4% / 33.33% · (Cash+Recv) / Total Assets 47.7% / 33.33% · Interest income / Revenue 5.20% / 5% | Fail |
No. As of September 2026, Omeros Corporation (OMER) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. Omeros Corporation is over the AAOIFI limit on Interest income / Revenue.
About 5.20% of each dividend: Omeros Corporation's interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.